Related by context. All words. (Click for frequent words.) 69 Dr. Michelle Berrey 68 receptor tyrosine kinase inhibitor 68 Thiovir 68 Pharmacokinetics PK 68 Initiate Phase 68 Aclidinium 68 nucleotide analog 67 multicenter Phase II 67 TRO# 67 Meets Primary Endpoint 67 fosbretabulin 67 Immunotherapeutic 67 PEG IFN 66 CCR5 mAb 66 Omacetaxine 66 HCD# [002] 66 TLK# 66 CCX# B 66 MAGE A3 ASCI 66 DermaVir Patch 66 AEGR 66 initiated Phase Ib 66 relapsed MM 66 phase Ib 66 elotuzumab 66 cilengitide 66 Panzem R NCD 66 liposomal formulation 66 GW# [003] 65 phase IIa 65 Copegus ribavirin 65 Phase 2b Clinical Trial 65 reslizumab 65 treatment naïve genotype 65 Blinatumomab 65 Aflibercept 65 Phase Ib clinical 65 mertansine 65 treatment naive genotype 65 forodesine 65 HIV coinfected 65 Initiates Clinical 65 PKC# 65 Onconase 65 preclinical efficacy 65 LymphoStat B TM 65 Factor VIIa 65 Initiated Phase 65 oral prodrug 65 nucleoside analog 65 non nucleoside inhibitor 65 polymerase inhibitor 65 oral antiviral 65 Hsp# Inhibitor 65 HGS ETR2 65 HQK 65 Phase 2a trial 65 PRTX 64 metaglidasen 64 pharmacokinetic PK study 64 telaprevir VX 64 Sapacitabine 64 phase IIa clinical 64 Phase IIIb clinical 64 multicenter Phase 64 JAK2 inhibitor 64 immunotherapeutic vaccine 64 Nancy Simonian MD 64 dose escalation clinical 64 Vascular Disrupting Agent 64 XL# SAR# 64 vidofludimus 64 AEG# 64 TASKi3 64 ChronVac C R 64 demonstrated antitumor activity 64 dose cohort 64 inhibitor RG# 64 Allovectin 7 64 Phase 1a 64 ELACYT 64 Phase IIb clinical trials 64 Sudhir Agrawal D.Phil 64 Maribavir 64 Successfully Completes Phase 64 antibody MAb 64 Aplidin 64 HBeAg + 64 Dacogen decitabine 64 ganetespib 64 Cloretazine 64 Aurora Kinase 64 Archexin 64 HGS# 64 Inhalation Solution 64 genotype 1a 64 PSMA ADC 64 Phase Ib II 64 PDE4 inhibitor 64 Cloretazine ® 64 including eniluracil ADH 64 orally administered inhibitor 63 TMC# [002] 63 Exherin TM 63 Janus Kinase 63 UPLYSO 63 CIMZIA TM 63 Multimeric 63 systemically administered 63 Phase 1a clinical 63 LymphoStat B belimumab 63 CCR5 antagonist 63 acetonide FA 63 Viramidine 63 Ozarelix 63 ritonavir boosted 63 Mohammad Azab MD 63 riociguat 63 pharmacodynamic profile 63 beta 1a 63 Pivotal Phase 63 Dr. McHutchison 63 Bezielle 63 alvespimycin 63 REG2 63 Harry Palmin President 63 RhuDex ® 63 systemic RNAi therapeutic 63 subcutaneous formulation 63 IMA# 63 Randomized Phase 63 Phase IIA 63 NP2 Enkephalin 63 cannabinor 63 baminercept 63 essential thrombocythemia ET 63 EndoTAG 63 HuMax EGFr 63 Aurora kinase inhibitor 63 controlled multicenter Phase 63 ATL/TV# 63 selective orally bioavailable 63 Pafuramidine 63 celgosivir 63 Protexia R 63 budesonide foam 63 Phase IIb trials 63 intranasal formulation 63 investigational oral hepatitis C 63 refractory gout 63 axitinib 63 phase 2a 63 Personalized Immunotherapy 63 PEG SN# 63 LUX Lung 63 velafermin 63 Aptivus ® 63 novel histone deacetylase 63 Phase Ib IIa 63 Phase 2b Trial 63 Traficet EN 63 EOquin TM 63 Kinoid 63 Dual Opioid 63 volociximab 63 Phase #b/#a clinical 63 ENGAGE AF TIMI 63 refractory CLL 63 Nicole Onetto MD 63 huC# DM4 63 adecatumumab MT# 63 thetreatment 63 Cloretazine R VNP#M 63 PEG Interferon lambda 63 novel VDA molecule 63 solithromycin 63 KRN# 63 Altastaph 63 Luteinizing Hormone Releasing Hormone 63 Ecallantide 63 Initiates Clinical Trial 63 Phase 2b clinical trials 63 PEGylated Fab fragment 63 eniluracil 62 KSP inhibitor 62 prucalopride 62 Epratuzumab 62 Safinamide 62 evaluating tivozanib 62 lintuzumab SGN 62 phase IIb III 62 FOLOTYN ® 62 targeting CD# 62 histone deacetylase HDAC inhibitor 62 midstage trials 62 Vitaxin 62 TASKi2 62 Vicriviroc 62 Darinaparsin 62 BAL# [002] 62 CCR9 antagonist 62 Tarvacin TM 62 Jean Francois Rossignol 62 BIM #A# 62 OMP #M# 62 G#DT 62 EndoTAG TM -1 62 phase IIb clinical 62 HGS ETR1 62 SinuNase TM 62 urocortin 2 62 OvaRex R 62 Achieves Primary Endpoint 62 SAR# [004] 62 cMET 62 Pazopanib 62 MKC# MT 62 mapatumumab 62 LB# [003] 62 Pagoclone 62 Phase 1b clinical trials 62 BrachySil TM 62 thalidomide Thalomid 62 PRT# 62 CRF1 receptor antagonist 62 assessing T DM1 62 safety tolerability pharmacokinetic 62 Multiple Ascending Dose 62 Amgen Neulasta ® 62 Afatinib 62 non splenectomized 62 dasatinib Sprycel ® 62 virus HCV protease inhibitor 62 isoform selective 62 oral Janus kinase 62 MEK inhibitor 62 Teriflunomide 62 First Patient Dosed 62 Vojo Vukovic MD Ph.D. 62 SinuNase ™ 62 Daclizumab 62 lumiliximab 62 ara C 62 investigational monoclonal antibody 62 Completes Patient Enrollment 62 Mycophenolate Mofetil 62 JAK inhibitor 62 phase Ib clinical 62 Initiates Phase II 62 CYT# potent vascular disrupting 62 sodium thiosulfate STS 62 phase IIb trial 62 Cethromycin 62 certolizumab 62 DEB# 62 erlotinib Tarceva ® 62 Azacitidine 62 Dr. Fahar Merchant 62 MGd 62 Panzem R 62 humanized monoclonal 62 Phase IIa trial 62 Phase Ib clinical trials 62 E1 INT TM 62 RSD# oral 62 IAP inhibitor 62 Civacir 62 Myelodysplastic Syndrome MDS 62 VivaGel TM 62 pan HDAC inhibitor 62 TroVax ® 62 Elacytarabine 62 HuLuc# 62 Pivotal Phase III 62 Carfilzomib 62 Bicifadine 62 docetaxel Taxotere R 62 orally bioavailable 62 selective modulator 62 nucleotide analogs 62 BRAF mutant 62 multicenter phase 62 ZACTIMA 62 R albinterferon alfa 62 randomized controlled Phase 62 #mg ATC 62 patientswith 62 Phase #b/#a trial 62 VNP#M 62 Kahalalide F 62 peginterferon alpha 2a 62 MVA BN 62 Phase IIb Trial 62 brivaracetam 62 Tarceva TM 62 sorafenib Nexavar 62 #I TM# 62 HCV protease inhibitors 62 alfa 2a 62 GOUT 62 neratinib 62 μg dose 62 ADP receptor antagonist 62 GRNVAC1 62 Cloretazine R 62 IFN α 62 Phase #b/#a 62 Zybrestat 61 phase IIb study 61 MGN# 61 pafuramidine 61 Mipomersen 61 immune globulin intravenous 61 OHR/AVR# 61 BENLYSTA ® 61 antiviral efficacy 61 midstage clinical 61 Trial Evaluating 61 FluCide 61 Prosaptide 61 Preclinical studies suggest 61 cystinosis patients 61 alpha 2a 61 Muraglitazar 61 DCCR 61 omega interferon 61 docetaxel Taxotere ® 61 soluble tumor necrosis 61 INSPIRE Trial Phase III 61 ISTODAX ® 61 HDAC Inhibitor 61 Nanobody 61 diabetic neuropathic pain 61 investigational humanized monoclonal antibody 61 immunomodulatory therapy 61 Pivotal Study 61 Annamycin 61 R#/MEM # 61 Eniluracil 61 Romidepsin 61 blinded randomized placebo controlled 61 GVAX ® 61 preclinically 61 octreotide acetate 61 Fc fusion protein 61 Acute Radiation Syndrome ARS 61 oral picoplatin 61 ORENCIA ® 61 Pivotal Phase II 61 Phase 1b clinical 61 motesanib diphosphate 61 HGS ETR1 mapatumumab 61 CD# monoclonal antibody 61 Spiro Rombotis President 61 DB# [003] 61 Phase 1b trial 61 Phase 2a 61 Begins Dosing 61 HCV polymerase 61 taxane resistant 61 galiximab 61 davunetide intranasal AL 61 CIMZIA TM certolizumab pegol 61 corticosteroid dexamethasone 61 PDX pralatrexate 61 trodusquemine 61 Phase IIa trials 61 CytoFabTM 61 MyVax ® 61 interferon α 61 Neulasta ® 61 pegylated interferon alpha 61 Xyfid TM 61 PHX# 61 torezolid 61 Parathyroid Hormone 61 AKT inhibitor 61 phase IIb 61 Pimavanserin 61 Insegia 61 phase III isavuconazole 61 Eric L. Dobmeier 61 inhaled AAT 61 Phase 2b Study 61 PSN# [002] 61 AVONEX ® 61 LAB CGRP 61 administered subcutaneously 61 nitazoxanide 61 abacavir Ziagen 61 Novolimus 61 Spiegelmer ® 61 rilonacept 61 gemcitabine cisplatin 61 tramiprosate Alzhemed TM 61 elacytarabine 61 alemtuzumab Campath 61 Investigational Oral 61 incyclinide 61 ATL# [002] 61 BrachySil ™ 61 pharmacodynamic properties 61 PPAR gamma agonist 61 Cethrin R 61 histone deacetylase inhibitor 61 EGFR HER2 61 Capesaris 61 Initiates Enrollment 61 pradefovir 61 DDP# 61 lucinactant 61 Phase III Clinical Trial 61 cathepsin K inhibitor 61 Phase IIa Clinical Trial 61 Elagolix 61 nalbuphine ER 61 APEX PD 61 Phase IIb Clinical Trial 61 Metastatic Melanoma 61 vinorelbine tartrate 61 ACOMPLIA R 61 subcutaneously administered 61 CLORETAZINE TM VNP#M 61 non nucleoside 61 Phase IIB 61 TG# [003] 61 huN# DM1 61 pertuzumab 61 placebo controlled Phase 61 ISTODAX 61 Betaferon R 61 im peramivir 61 Phase 1b 61 VIR# 61 leukemia AML 61 retinal vein occlusion induced 61 lomitapide 61 registrational trial 61 sitaxsentan 61 radezolid 61 tipranavir r 61 metastatic malignant 61 CRMD# 61 Safi Bahcall Ph.D. 61 PSN# [001] 61 Sym# 61 targeted radiotherapeutic 61 PEGPH# 61 Zoraxel 61 Apaziquone 61 miconazole Lauriad 61 HuMax CD4 61 apricitabine 61 Clinical Trial Results 61 eritoran 61 multicenter randomized Phase 61 Alferon N 61 radiation sensitizer 61 null responder 61 Intravitreal 61 ® interferon beta 60 TransVax 60 Peginterferon alfa 2b 60 interferon gamma 1b 60 prokinetic agent 60 CTAP# Capsules 60 IMC #B 60 HDACi 60 cynomolgus monkeys 60 gefitinib Iressa 60 OncoVEX GM CSF 60 diarrhea predominant irritable 60 Phase Ib study 60 TKB# 60 unresectable stage 60 polycythemia vera essential thrombocythemia 60 intradermal injections 60 PegIFN RBV 60 drug conjugate 60 SNT MC# 60 pomalidomide 60 ACTEMRA TM 60 obatoclax 60 Diamyd r 60 otelixizumab 60 JVRS 60 mGluR5 NAM 60 rALLy clinical trial 60 apricitabine ATC 60 masitinib 60 acyclovir Lauriad R 60 teriflunomide 60 Virulizin ® 60 visilizumab 60 cariprazine 60 Plicera 60 recurrent herpes labialis 60 lintuzumab 60 gemtuzumab ozogamicin 60 HDL Selective Delipidation 60 HuMax CD# 60 CA9 SCAN 60 Commences Phase 60 Pharmacodynamics 60 ACAPODENE TM 60 CCX# 60 XL# XL# 60 PI3K/Akt pathway inhibitor 60 ceftazidime 60 Phase #/#a 60 Alinia 60 DP b# 60 ARC# [001] 60 Dr. Arndt Schottelius 60 MT# MEDI 60 TBC# 60 non nucleoside HCV 60 CEQ# 60 Alvesco R 60 Anidulafungin 60 RhD positive 60 Allovectin 7 R 60 PXD# 60 intravenously administered 60 Neugene 60 p# inhibitor 60 Phase IIb III 60 antiretroviral naïve 60 Apoptone 60 aurora kinase inhibitor 60 brivanib 60 PGL# 60 TELINTRA 60 fidaxomicin Phase 60 invasive candidiasis 60 dose escalation Phase 60 IMVAMUNE TM 60 Pegloticase 60 ofatumumab HuMax CD# 60 AAG geldanamycin analog 60 HER2 antibody 60 CBLC# 60 Confirmatory Phase 60 THR beta agonist 60 amrubicin 60 IPL# 60 tolerability pharmacokinetics 60 HuMax 60 liposomal doxorubicin 60 ALN HPN 60 Fabry Disease 60 INCB# [001] 60 afamelanotide 60 omacetaxine mepesuccinate 60 lenalidomide Revlimid 60 HCl Tablets 60 Fluconazole 60 recurrent glioblastoma multiforme 60 dose cohorts 60 CR# vcMMAE 60 TLR9 agonist 60 hormone LHRH antagonist 60 PEG interferon 60 TH# [003] 60 somatostatin analog 60 CLL SLL 60 topically administered 60 Phase III Clinical Trials 60 Reports Preclinical Data 60 Intarcia 60 #mg QD [002] 60 ganaxolone 60 subcutaneous immunoglobulin 60 Dr. Aiping Young 60 generation antisense inhibitor 60 Glypromate 60 SNT-MC#/idebenone 60 CRLX# 60 humanized monoclonal antibody 60 maximally tolerated dose 60 sodium glucose cotransporter 60 Interferon alpha 60 metastatic hormone refractory 60 dexanabinol 60 ascending dose 60 Irinotecan 60 Dr. Jaap Goudsmit 60 TransVax tm 60 TKM ApoB 60 Clolar ® 60 CDK inhibitor 60 TRX1 60 receptor monoclonal antibody 60 Tasimelteon 60 Darusentan 60 Michel Morre DVM 60 renin inhibitor 60 SPRYCEL ® 60 small molecule tyrosine 60 MYCAMINE 60 BioNumerik 60 Dacogen injection 60 gemcitabine carboplatin 60 PANVAC VF 60 investigational pan BCR 60 oral treprostinil 60 OMP #R# 60 TransVax ™ 60 2 methoxyestradiol 60 oral ridaforolimus 60 hypoxia activated prodrug 60 novel therapeutic antibodies 60 PD LID 60 atacicept 60 Degarelix 60 Neulasta R 60 Iris Loew Friedrich 60 RELOVAIR ™ 60 Initiates Phase 60 AQ4N 60 antisense drug 60 ATL# [001] 60 dacetuzumab 60 Triapine 60 Aliskiren 60 anti CTLA 60 Tesetaxel 60 piperacillin tazobactam 60 INS# [001] 60 Enzastaurin 60 Phase 2a Clinical Trial 60 FVIIa 60 pharmacokinetics PK 60 mitoxantrone plus 60 Phase 2b trial 60 Efficacy Trial 60 eprotirome 60 Initiates Phase III 60 5 fluorouracil leucovorin 60 FOLFIRI chemotherapy 60 Phase Ia 60 catheter occlusion 60 torezolid phosphate 60 elvucitabine 60 TG# [001] 60 Phase III Pivotal 60 Symadex 60 Phase 2a clinical 60 partial agonist 60 CA4P 60 randomized Phase IIb 60 Anthim 60 MAXY alpha 60 oral ghrelin agonist 60 canakinumab 60 Tyrima 60 Xeloda ® 60 Aplidin R 60 Rebif ® 60 Forodesine HCl 60 trastuzumab DM1 T DM1 60 Mark A. Sirgo 60 Lenocta TM 60 CINTREDEKIN BESUDOTOX 60 multicenter randomized placebo controlled 60 DU #b 60 Myocet 60 abacavir lamivudine 60 proteasome inhibitor 60 PEGylated interferon 60 peripherally acting 60 GRN# 60 CCR5 inhibitor 60 Vidofludimus 60 Amrubicin 60 velafermin belinostat 60 FOLFOX chemotherapy 60 initiated Phase 1b 60 oxymorphone ER 60 Elocalcitol 60 dasatinib Sprycel 60 gamma secretase inhibitor 60 sunitinib malate 60 Janus kinase 60 Cancidas 60 constipation predominant irritable bowel 60 AOD# [002] 60 PDE# inhibitors 60 S/GSK# 60 humanised monoclonal antibody 60 Hedgehog antagonist 60 GV# [001] 59 Dr Bernd Hentsch 59 ALN VSP Phase 59 Æterna Zentaris 59 Prodarsan 59 Lenocta 59 multicenter Phase III 59 Novel Small Molecule 59 Phase IIb 59 RhuDex 59 HIV integrase inhibitor 59 II Clinical Trial 59 docetaxel Taxotere 59 Dalbavancin 59 FOR FURTHER INFORMATION ABOUT 59 Cytochrome P# 59 clevidipine 59 HCV SPRINT 59 MTP inhibitor 59 ARIKACE ™ 59 JAK inhibitors 59 herpetic keratitis 59 monoclonal antibody MAb 59 Elvitegravir 59 HIV integrase inhibitors 59 long acting muscarinic 59 Guanilib 59 Wellstat 59 apoptosis inducer 59 targeted antifolate 59 RhuDex R 59 XmAb 59 tanespimycin 59 HuMax HepC TM 59 CIMZIA ™ 59 zanolimumab 59 LAF# 59 Japanese Encephalitis vaccine 59 Barry D. Quart 59 Belerofon 59 atazanavir ritonavir 59 BN# [004] 59 adenosine A2A 59 Anturol TM 59 Zenvia ™ 59 Xanafide 59 IV Busulfex 59 SCH # 59 haematological cancers 59 inhaled iloprost 59 OMNARIS HFA 59 viral kinetics 59 relapsed multiple myeloma 59 aflibercept VEGF Trap 59 Behcet uveitis 59 Imprime PGG 59 Phase Ib 59 cetuximab Erbitux R 59 Phase 2b 59 Lupuzor 59 Antiviral Activity 59 ONCONASE R 59 Study Evaluating 59 samalizumab 59 Prulifloxacin 59 4SC commented 59 antifibrotic 59 ospemifene 59 TG MV 59 sargramostim 59 bendamustine 59 Ceflatonin R 59 GLPG# 59 RhuDex TM 59 rindopepimut 59 MyVax personalized immunotherapy 59 Ataluren 59 chimeric monoclonal antibody 59 ocrelizumab 59 ZOLINZA 59 ribavirin RBV 59 ADVANCE PD 59 ChronVac C ® 59 RAPTIVA 59 PF # [002] 59 personalized immunotherapy 59 Anticancer Compound 59 Cetrorelix 59 oral FTY# 59 SGLT 59 TMC# C# 59 MKC# 59 GMX# 59 paclitaxel poliglumex 59 MET inhibitor 59 Allovectin 7 ® 59 idiopathic thrombocytopenic purpura 59 HCV Genotype 59 registrational clinical 59 therapeutic monoclonal antibody 59 Dose Ranging Study 59 Interferon alfa 59 delivers fluocinolone acetonide FA 59 Phase 2b study 59 Zenvia Phase III 59 Deferiprone 59 initiate Phase 1b 59 lenalidomide Revlimid R 59 bardoxolone 59 Ramoplanin 59 Martin Nicklasson CEO 59 subcutaneous PRO 59 relapsing multiple sclerosis 59 pharmacodynamic PD 59 DPX Survivac 59 oncolytic virus therapies 59 Exelixis XL# 59 PROCHYMAL 59 Onrigin 59 GSK '# 59 relapsing remitting MS RRMS 59 Neupogen ® 59 dirucotide MBP# 59 Combination REOLYSIN R 59 PNP inhibitor 59 Anavex #-# 59 aclidinium bromide 59 humanized anti 59 oral salmon calcitonin 59 oral RSD# 59 IRX 2 59 BENLYSTA ™ 59 castrate resistant prostate cancer 59 DXL# 59 HspE7 59 Enzyme Replacement Therapy 59 AIMM trial 59 alkylating agent 59 oral talactoferrin 59 Vascugel 59 Dr. Karl Mettinger 59 HCV Protease Inhibitor 59 metastatic colorectal 59 TPI ASM8 59 VELCADE melphalan 59 isavuconazole 59 Vidaza azacitidine 59 docetaxel chemotherapy 59 metastatic CRC 59 deforolimus 59 GLP1 agonist 59 vinca alkaloid 59 Protease Inhibitor 59 beta interferons 59 Diamyd ® 59 Fx #A 59 Pradefovir 59 MVA nef 59 Ridaforolimus 59 Glufosfamide 59 Actimmune ® 59 Denufosol 59 epigenetic therapies 59 Kamada AAT 59 Pivotal Trial 59 Aganocide 59 myeloproliferative diseases 59 Arranon 59 lapatinib Tykerb 59 APTIVUS 59 immunomodulator 59 #mg BID [003] 59 TACI Ig 59 tipranavir 59 IMC A# 59 fluticasone furoate 59 Bosutinib 59 dexamethasone Decadron 59 Proxinium TM 59 Acute Ischemic Stroke 59 CytoFab 59 maturation inhibitor 59 MCSP respectively 59 myelodysplastic myeloproliferative diseases 59 Granted Orphan Drug 59 Diabetic Neuropathy 59 recurrent glioblastoma 59 Granulocyte Colony Stimulating Factor 59 Armando Anido Chief Executive 59 Testosterone MDTS ® 59 vapreotide acetate 59 tarenflurbil 59 PEGylated interferon beta 1a 59 ongoing Phase 1b 59 Nexavar sorafenib 59 selective phosphodiesterase 59 Omacetaxine mepesuccinate 59 Interferon beta 59 Triapine R 59 hoFH 59 initiate Phase IIa 59 MDS AML 59 NOX E# 59 aerosolized AAT 59 VitiGam TM 59 Troxatyl TM 59 pain palliation 59 BCIRG 59 Solazed 59 GLYX 59 Panzem ® 59 CD3 monoclonal antibody 59 dextromethorphan quinidine 59 selective antagonist 59 highly selective inhibitor 59 SYN# 59 Exherin 59 IFN alfa 59 Intravail ® 59 NN# [001] 59 Shigamabs ® 59 Liposomal 59 Quinamed 59 afatinib 59 Solulin 59 relapsed refractory multiple myeloma 59 HSP# inhibitor 59 BIIB# 59 micafungin 59 Talactoferrin 59 naïve HCV 59 Oglemilast 59 AzaSite TM 59 satraplatin Phase 59 Ophena TM 59 AZX# Phase 59 PEG PAL 59 liposome injection 59 Lixivaptan 59 lenalidomide dexamethasone 59 Initiates Phase 2b 59 mTOR inhibitors 59 ascending doses 59 novel oral anticoagulant 59 viral kinetic 58 Perifosine 58 ancrod 58 ESBA# 58 NO# [002] 58 retaspimycin 58 histamine dihydrochloride 58 MOVIPREP R 58 BLyS specific 58 SCIB1 58 PRESEPT 58 bevacizumab Avastin ® 58 DCVax R 58 J. Donald deBethizy 58 EVIZON TM 58 glatiramer acetate 58 Xelox 58 dosed orally 58 Phase #/#a trial 58 Zalypsis 58 YONDELIS 58 Hepatotoxicity 58 Ulrich Dauer CEO 58 DuraSite 58 rNAPc2 58 APTIVUS r 58 pharmacodynamic effects 58 Alocrest 58 IFN β 58 nucleoside reverse transcriptase inhibitor 58 MKC# MKC# PP 58 dosing cohort 58 Silodosin 58 Bayer HealthCare Onyx Pharmaceuticals 58 trastuzumab Herceptin R 58 potent antiproliferative 58 pathophysiological effects 58 Phase IIa 58 Anthony Giovinazzo 58 hypereosinophilic syndrome 58 Chronic Hepatitis C 58 Pegasys peginterferon alfa 2a 58 biologic DMARD 58 tezampanel NGX# 58 CG# [003] 58 Phase 2a Study 58 Tanespimycin 58 Amgen Neulasta R 58 HCV NS5B polymerase 58 ProLindac TM 58 HCV polymerase inhibitor 58 GALNS 58 valopicitabine 58 protein tyrosine phosphatase 1B 58 ASONEP 58 sulodexide 58 Interferon beta 1b 58 stated Belinda Tsao 58 bicifadine 58 L BLP# 58 Mpex 58 generation purine nucleoside 58 Yondelis ® 58 talactoferrin